News Breaks |
|
|
| November 14, 2012 |
| 07:44 EDT |  | INCY, LLY | Incyte weakness creates buying opportunity, says Oppenheimer
After Incyte (INCY) and partner Eli Lilly (LLY) reported Phase IIb results for their baricitinib in rheumatoid arthritis, Oppenheimer expects the drug to be approved in 2015-2016. The firm thinks the baricitinib program is doing well, and it maintains a $23 price target and Outperform rating on Incyte. |
|
|
News For INCY;LLY From The Last 14 Days Check below for free stories on INCY;LLY the last two weeks. |
|
|
| May 21, 2013 |
| 07:24 EDT |  | LLY | Global Health Care to host a conference
 Subscribe for More Information |
|
| May 16, 2013 |
| 08:55 EDT | | LLY | BofA/Merrill's pharmaceuticals analysts hold analyst/industry conference call
Subscribe for More Information |
|
| May 14, 2013 |
| 09:09 EDT |  | LLY | Eli Lilly announces CEO John Lechleiter recovering from surgery
Subscribe for More Information |
|
| 07:24 EDT | | LLY | EBD Group to host a conference
BioTrinity 2013 is being held in Newbury, England on May 14-16. |
|
| May 10, 2013 |
| 11:48 EDT |  | LLY | Drugmakers to face pressure on U.S. prices, Reuters says
Subscribe for More Information |
|
| 08:02 EDT | | LLY | Eli Lilly's Enzastaurin Phase III study did not meet primary endpoint
Eli Lilly announced Phase III clinical trial results from enzastaurin's PRELUDE study, which explored the molecule as a monotherapy in the prevention of relapse in patients with diffuse large B-cell lymphoma. The study failed to show a statistically significant increase compared to placebo in disease-free survival in patients at high risk of relapse following rituximab-based chemotherapy. There were no new safety findings, and the safety data were consistent with previously disclosed studies. Lilly will stop development of enzastaurin, which is expected to result in a second-quarter charge to R&D expense of approximately $30M. The company's previously-issued financial guidance for 2013 remains unchanged. |
|
|
|
|
|
